Caerus Investment Advisors LLC Trims Stock Position in Medpace Holdings, Inc. $MEDP

Caerus Investment Advisors LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 774 shares of the company’s stock after selling 1,523 shares during the period. Caerus Investment Advisors LLC’s holdings in Medpace were worth $372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter worth about $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. Quarry LP acquired a new position in shares of Medpace in the 3rd quarter valued at about $35,000. Bayban purchased a new stake in shares of Medpace in the fourth quarter worth about $44,000. Finally, Core Wealth Advisors LLC purchased a new stake in shares of Medpace in the fourth quarter worth about $47,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 0.2%

NASDAQ:MEDP opened at $577.11 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock has a market capitalization of $16.11 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.57 and a beta of 1.15. The stock’s 50-day moving average price is $507.61 and its 200-day moving average price is $493.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent research reports. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Truist Financial upped their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $584.18.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 3,510 shares of Medpace stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total transaction of $2,106,035.10. Following the completion of the sale, the chief executive officer directly owned 638,946 shares in the company, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 31,087 shares of company stock valued at $16,203,054. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.